Obinutuzumab approved for CLL: Monoclonal antibody product is first FDA-approved breakthrough therapy

Published 2013 View Full Article

  1. Home
  2. Publications
  3. Publication Search
  4. Publication Details
Title
Obinutuzumab approved for CLL: Monoclonal antibody product is first FDA-approved breakthrough therapy
Authors
Keywords
-
Journal
AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY
Volume 70, Issue 24, Pages 2162-2162
Publisher
American Society of Health System Pharmacists
Online
2013-12-03
DOI
10.2146/news130080

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Reprint

Contact the author

Discover Peeref hubs

Discuss science. Find collaborators. Network.

Join a conversation

Become a Peeref-certified reviewer

The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.

Get Started
Webinars Posters Questions Hubs Funding Journals Articles Connect Collections Reviewers About Us FAQs Mobile App Privacy Policy Terms of Use
© Peeref 2019-2024. All rights reserved.